Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Muller, WJ; Madhi, SA; Seoane, Nuñez, B; Baca, Cots, M; Bosheva, M; Dagan, R; Hammitt, LL; Llapur, CJ; Novoa, JM; Saez, Llorens, X; Grenham, A; Kelly, EJ; Mankad, VS; Shroff, M; Takas, T; Leach, A; Villafana, T, , MELODY, Study, Group;the, MELODY, Study, Group.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med. 2023; 388(16): 1533-1534. Doi: 10.1056/NEJMc2214773
Web of Science PubMed FullText FullText_MUG

Study Group Members Med Uni Graz:: Resch Bernhard
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Nirsevimab to Prevent RSV Illness in InfantsNirsevimab, a monoclonal antibody targeting respiratory syncytial virus, protected against RSV-associated hospitalization and severe lower respiratory tract infection in term and late-preterm infants.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Infant - administration & dosage; Infant, Newborn - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antiviral Agents - therapeutic use; Hospitalization - administration & dosage; Infant, Premature - administration & dosage; Palivizumab - administration & dosage; Respiratory Syncytial Virus Infections - prevention & control, drug therapy; Term Birth - administration & dosage; Infant, Newborn, Diseases - drug therapy, prevention & control